Physician

Saurabh A Pande, M.D

According to 2025 Medicare claims, Saurabh Pande, M.D (NPI: 1689888307) practices nephrology in the El Paso, TX market, with the plurality of this provider's patient population coming from El Paso, TX. This provider's primary affiliated billing organization is SAURABH A PANDE PA (NPI: 1881100972; TIN: 823794685) and primary practice location at 79902-3524.

Pande's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 679 traditional Medicare patients, billed 2,542 HCPCS/CPT codes, and received $367,132 in Medicare payments. The top billing code was 99291 (Critical care, first 30-74 minutes). Part D data shows 2,421 prescription claims across 360 beneficiaries totaling $566,826 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 68 claims. Open Payments data shows 31 records totaling $604. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $486,479 and ending at $566,826. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $200 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	754	7,370	$423,185
2016	733	7,890	$461,134
2017	857	9,562	$511,029
2018	855	7,821	$520,794
2019	893	8,821	$720,557
2020	823	6,902	$627,235
2021	728	4,331	$482,806
2022	663	3,297	$406,181
2023	670	2,769	$379,978
2024	679	2,542	$367,132

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	337	1,931	$486,479
2016	377	2,137	$615,086
2017	434	2,245	$594,608
2018	488	2,332	$320,499
2019	509	2,328	$513,203
2020	544	2,599	$349,767
2021	468	2,489	$405,558
2022	358	1,997	$472,482
2023	284	2,085	$478,853
2024	360	2,421	$566,826

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	15	$400
2016	N/R	35	$1,462
2017	N/R	83	$3,430
2018	N/R	114	$4,407
2019	N/R	234	$13,730
2020	N/R	140	$3,778
2021	N/R	129	$2,869
2022	N/R	39	$623
2023	N/R	66	$1,445
2024	N/R	68	$813

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99291	Critical care, first 30-74 minutes	165	371	$171
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	405	487	$137
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	72	150	$97
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	136	320	$94
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	115	223	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	48	1,440	$134,281
Veltassa	Patiromer Calcium Sorbitex	66	2,710	$88,753
Xphozah	Tenapanor Hcl	28	900	$86,619
Sevelamer Carbonate	Sevelamer Carbonate	187	11,568	$40,746
Auryxia	Ferric Citrate	25	827	$29,672

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	25	$301
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	18	$282
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	14	$222
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	11	$8

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	31	$604	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Saurabh A. Pande, M.D?

Tedicare shows public-source Medicare data for Saurabh A. Pande, M.D (NPI 1689888307), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Saurabh A. Pande, M.D have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Saurabh A. Pande, M.D?

Saurabh A. Pande, M.D is linked to SAURABH A PANDE PA (billing NPI 1881100972) in the available physician profile data.

Does Saurabh A. Pande, M.D have Open Payments data?

Saurabh A. Pande, M.D has 31 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.